Peritumoral endothelial indoleamine 2, 3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA mismatch repair profile

Targeting immune checkpoint molecules has become a major new strategy in the treatment of several cancers. Indoleamine 2,3-dioxygenase (IDO)-inhibitors are a potential next-generation immunotherapy, currently investigated in multiple phase I-III trials. IDO is an intracellular immunosuppressive enzy...

Descripción completa

Detalles Bibliográficos
Autores principales: Meireson, Annabel, Chevolet, Inès, Hulstaert, Eva, Ferdinande, Liesbeth, Ost, Piet, Geboes, Karen, De Man, Marc, Van de Putte, Dirk, Verset, Laurine, Kruse, Vibeke, Demetter, Pieter, Brochez, Lieve
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982767/
https://www.ncbi.nlm.nih.gov/pubmed/29861865
http://dx.doi.org/10.18632/oncotarget.25393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982767/
https://www.ncbi.nlm.nih.gov/pubmed/29861865
http://dx.doi.org/10.18632/oncotarget.25393

Ejemplares similares